Vitiligo: Current Therapies and Future Treatments
Keywords:
vitiligo, management, treatmentAbstract
The current management of vitiligo remains challenging; however, different strategies can be proposed to patients with a good efficacy in many cases. First, it is important to identify patients in the active phase of the disease because treatment should start as soon as possible to halt its progression. For patients with a stable disease, the treatment strategy is now well-stratified and is based on a combination of phototherapy (natural or in a cabin) and topical immunomodulatory agents. Surgical treatments are useful for localized and stable vitiligo, as well as for segmental vitiligo. Depigmentation remains indicated in very extensive forms. The recent approval of topical ruxolitinib cream in both the US and Europe brings new approaches for the management of vitiligo and paves the way for the development of new topical or oral targeted drugs.
References
Geel N, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol 2023.
Seneschal J, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations. J Eur Acad Dermatol Venereol 2023.
Zhang L, Chen S, Kang Y, et al. Association of Clinical Markers With Disease Progression in Patients With Vitiligo From China. Jama Dermatol 2020;156.
Sosa JJ, Currimbhoy SD, Ukoha U, et al. Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo. J Am Acad Dermatol 2015;73:272–5.
Geel N van, Speeckaert R, Wolf JD, et al. Clinical significance of Koebner phenomenon in vitiligo. Brit J Dermatol 2012;167:1017–24.
Geel N van, Grine L, Wispelaere PD, Mertens D, Prinsen CAC, Speeckaert R. Clinical visible signs of disease activity in vitiligo: a systematic review and meta‐analysis. J Eur Acad Dermatol Venereol 2019;33:1667–75doi:10.1111/jdv.15604.
Geel N van, Passeron T, Wolkerstorfer A, Speeckaert R, Ezzedine K. Reliability and validity of the Vitiligo Signs of Activity Score (VSAS). Brit J Dermatol 2020.
Passeron T. Medical and Maintenance Treatments for Vitiligo. Dermatol Clin 2017;35:163–70.
Tovar-Garza A, Hinojosa JA, Hynan LS, Pandya AG. Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo. The British journal of dermatology 2019;180:193–4.
Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004;140:1065–9.
Seneschal J, Duplaine A, Maillard H, et al. Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study. J Investig Dermatol 2021;141:1728–34.
Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Archives of Dermatology 2003;139:581–5.
Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. New Engl J Med 2022;387:1445–55.
Esmat SM, El‐Mofty M, Rasheed H, et al. Efficacy of narrow band UVB with or without OMP in stabilization of vitiligo activity in skin photo‐types (III–V): A double‐blind, randomized, placebo‐controlled, prospective, multicenter study. Photodermatol Photoimmunol Photomed 2021.
Esmat S, Hegazy RA, Shalaby S, Hu SC-S, Lan C-CE. Phototherapy and Combination Therapies for Vitiligo. Dermatologic clinics 2017;35:171–92.
Esmat S, Mostafa W, Hegazy RA, et al. Phototherapy: The vitiligo management pillar. Clin Dermatol 2016;34:594–602.
Mohammad TF, Al-Jamal M, Hamzavi IH, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. Journal of the American Academy of Dermatology 2017;76:879–88.
Mohammad TF, Silpa-Archa N, Griffith JL, Lim HW, Hamzavi IH. Home phototherapy in vitiligo. Photodermatology, Photoimmunology & Photomedicine 2017;33:241–52.
Batchelor JM, Millington A, Thomas KS, et al. Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT. Heal Technol Assess 2020;24:1–128.
Teulings HE, Overkamp M, Ceylan E, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. British Journal of Dermatology 2012;168:162–71doi:10.1111/bjd.12111.
Bae JM, Ju HJ, Lee RW, et al. Evaluation for Skin Cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy. Jama Dermatol 2020;156:529–37.
Ju HJ, Han JH, Kim M-S, et al. The long-term risk of lymphoma and skin cancer was not increased after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo. J Am Acad Dermatol 2021.
Mohammad TF, Hamzavi IH. Surgical Therapies for Vitiligo. Dermatologic clinics 2017;35:193–203.
Ju HJ, Bae JM, Lee RW, et al. Surgical Interventions for Patients With Vitiligo. JAMA Dermatol 2021;157:307–16.
Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol 2007;56:274–8.
Cavalié M, Ezzedine K, Fontas E, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. The Journal of investigative dermatology 2015;135:970–4.
Komen L, Zwertbroek L, Burger SJ, Veen JPW, Rie MA, Wolkerstorfer A. Q‐switched laser depigmentation in vitiligo, most effective in active disease. Brit J Dermatol 2013;169:1246–51.
MOSHER DB, PARRISH JA, FITZPATRICK TB. Monobenzylether of hydroquinone. Brit J Dermatol 1977;97:669–79.
Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J Am Acad Dermatol 2023;88:395–403.
Richmond JM, Strassner JP, Zapata L, et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med 2018;10:eaam7710.
Jacquemin C, Rambert J, Guillet S, et al. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. The British journal of dermatology 2017;177:1367–75.
Mosenson JA, Eby JM, Hernandez C, Poole ICL. A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Experimental Dermatology 2013;22:566–9.
Mosenson JA, Zloza A, Nieland JD, et al. Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo. Science translational medicine 2013;5:174ra28-174ra28.
Boukhedouni N, Martins C, Darrigade A-S, et al. Type-1 cytokines regulate matrix metalloprotease-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. Jci Insight 2020.
Bzioueche H, Sjödin KS, West CE, et al. Analysis of Matched Skin and Gut Microbiome of Patients with Vitiligo Reveals Deep Skin Dysbiosis: Link with Mitochondrial and Immune Changes. J Invest Dermatol 2021;141:2280–90.
Regazzetti C, Joly F, Marty C, et al. Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients. J Invest Dermatol 2015;135:3105–14.
Published
Issue
Section
License
Copyright (c) 2023 SENESCHAL Julien, Katia BONIFACE
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
